Free Trial

Stock Analyst Initiations

Track the latest stock analyst initiations, newly initiated coverage, and first-time analyst ratings in this regularly updated list of analyst recommendations. This page compiles new initiations, including initial stock ratings, buy/hold/sell recommendations, and price targets, so you can monitor all recent coverage openings across the market.

0 Results
CompanyActionBrokerageAnalystCurrent PricePrice TargetRatingDetails
Aeluma, Inc. stock logo
ALMU
Aeluma
Initiated by $7.52
-0.3%
$16.00Outperform
AngloGold Ashanti PLC stock logo
AU
AngloGold Ashanti
Initiated by $82.15
+3.0%
$123.00Buy
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
Initiated by$1.42
-6.6%
Buy
Figma, Inc. stock logo
FIG
Figma
Initiated by$22.16
+2.4%
$23.00Neutral
FMC Corporation stock logo
FMC
FMC
Initiated by$6.49
+4.6%
$6.00Hold
H2O America stock logo
HTO
H2O America
Initiated by$61.19
+2.4%
$67.00Outperform
Janus Living, Inc. stock logo
JAN
Janus Living
Initiated by$28.46
-0.2%
$33.00Outperform
Nkarta, Inc. stock logo
NKTX
Nkarta
Initiated by$1.52
-2.6%
Buy
Nano Nuclear Energy Inc. stock logo
NNE
Nano Nuclear Energy
Initiated by $10.96
-5.9%
Outperform
Oracle Corporation stock logo
ORCL
Oracle
Initiated by $118.79
-9.1%
Buy
Government Document Reveals Plan To Control Your Money (it will disturb you) (Ad)

A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.tc pixel

Click here to see the document and learn protective steps
Oracle Corporation stock logo
ORCL
Oracle
Initiated by$118.79
-9.1%
Buy
Retension Pharmaceuticals, Inc. stock logo
RTSN
Retension Pharmaceuticals
Initiated by$11.30
-0.5%
$55.00Buy
SharkNinja, Inc. stock logo
SN
SharkNinja
Initiated by$213.35
+2.6%
$245.00Buy
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
Initiated by$40.84
-3.0%
$52.00Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:58 AM ET.

Frequently Asked Questions

Analyst ratings are the "buy" and "sell" labels, plus price targets, that investment researchers attach to specific securities. These ratings are based on financial data, earnings reports  and conversations with company executives.

Analyst ratings provide plenty of helpful information, but you shouldn't use an analyst's "buy" rating as the sole reason you purchase a security. Analysts aren't immune to conflicts of interest or outside parties' influence, so ensure you always understand why a stock was labeled a "buy" or "sell."

Ratings give investors the analyst's overall opinion about a particular stock and price targets based on the company's valuation and prospects. Analysts often attend conference calls, ask questions and provide in-depth information about companies that are difficult to acquire elsewhere.